Date: 2014-10-14
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in San Diego, United States
Company: Mologen (Germany)
Product: EnanDIM technology
Action
mechanism: EnanDIM® (Enantiomeric, DNA-based, ImmunoModulator) is a new class of enantiomeric oligodeoxynucleotides for TLR-9 activation. It represents a new generation of the company’s immunoactivating TLR-9 agonists that is expected to trigger a broad immune activation while being well tolerated. DNA-based TLR-9 agonists are potent activators of the innate immune system and of a variety of immune cell populations. So far, two different types of TLR-9 agonists have been established. The first consists of linear, single-stranded DNA molecules. Most of these linear TLR-9 agonists are chemically modified to protect them against degradation, which is known to produce off-target effects and toxicity. MOLOGEN’s lead product, the cancer immunotherapy MGN1703, represents the second type of TLR-9 agonist, a covalently-closed, dumbbell-shaped DNA molecule. As it consists entirely of natural DNA components, it is safe and well tolerated. EnanDIM® combines the immunoactivatory properties of molecules containing only natural DNA components with the advantages of linear molecules. Despite its linear structure, no chemical modifications are needed as the specific linear structure of EnanDIM protects the molecules against degradation. This protection is achieved by incorporation of mirror-imaged components, which are chemically identical to the naturally occurring DNA components but that are not recognized by DNA-degrading enzymes. Consequently, a favorable safety and tolerability profile is expected to be shown in the planned subsequent preclinical and clinical development.
Disease:
Therapeutic area: Cancer - Oncology - Infectious diseases
Country:
Trial details:
Latest
news: * On October 14, 2014, Mologen has presented preclinical data on its EnanDIM technology at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in San Diego, United States. EnanDIM represents a new generation of the company’s immunoactivating TLR-9 agonists that is expected to trigger a broad immune activation while being well tolerated. Potential applications include the fields of anti-tumor and anti-infective therapies. The broad immune activation induced by EnanDIM in preclinical models has been presented at OTS in an oral presentation. Therefore, the mode of action should enable the use in various cancer indications either as monotherapy, in combination with other targeted therapies or immune modulators, such as so called checkpoint inhibitors or with other immunotherapeutic approaches. Furthermore, it could potentially be used in the field of infectious diseases. Detailed information on EnanDIM, as discussed at the oral presentation, is summarized in the poster with the title “EnanDIM: A new class of enantiomeric oligodeoxynucleotides for TLR?9 activation” (poster no. 056).
